Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bexarotene therapy for mycosis fungoides and Sézary syndrome
Rachel Abbott, Sean Whittaker, Steven Morris, et al.
British Journal of Dermatology (2009) Vol. 160, Iss. 6, pp. 1299-1307
Closed Access | Times Cited: 113

Showing 1-25 of 113 citing articles:

European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017
Franz Trautinger, Johanna Eder, Chalid Assaf, et al.
European Journal of Cancer (2017) Vol. 77, pp. 57-74
Open Access | Times Cited: 419
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Sarah I. Jawed, Patricia L. Myskowski, Steven Horwitz, et al.
Journal of the American Academy of Dermatology (2014) Vol. 70, Iss. 2, pp. 205.e1-205.e16
Closed Access | Times Cited: 353
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)
Sarah I. Jawed, Patricia L. Myskowski, Sarah McCue Horwitz, et al.
Journal of the American Academy of Dermatology (2014) Vol. 70, Iss. 2, pp. 223.e1-223.e17
Closed Access | Times Cited: 326
Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy
Charlotte FM Hughes, Amit Khot, Christopher McCormack, et al.
Blood (2014) Vol. 125, Iss. 1, pp. 71-81
Open Access | Times Cited: 202
Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects
Samar Khalil, Tara Bardawil, Carla Stephan, et al.
Journal of Dermatological Treatment (2017) Vol. 28, Iss. 8, pp. 684-696
Closed Access | Times Cited: 179
EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023
Johanna Latzka, Chalid Assaf, M. Bagot, et al.
European Journal of Cancer (2023) Vol. 195, pp. 113343-113343
Open Access | Times Cited: 67
Sézary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC)
Elise A. Olsen, Alain H. Rook, John A. Zic, et al.
Journal of the American Academy of Dermatology (2010) Vol. 64, Iss. 2, pp. 352-404
Closed Access | Times Cited: 161
Retinoids and rexinoids in cancer prevention: from laboratory to clinic
Iván P. Uray, Ethan Dmitrovsky, Powel H. Brown
Seminars in Oncology (2015) Vol. 43, Iss. 1, pp. 49-64
Open Access | Times Cited: 143
Cutaneous T‐cell lymphoma: 2017 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2017) Vol. 92, Iss. 10, pp. 1085-1102
Open Access | Times Cited: 141
Cutaneous T‐cell lymphoma: 2016 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2015) Vol. 91, Iss. 1, pp. 151-165
Open Access | Times Cited: 139
British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018
D. Gilson, Sean Whittaker, Fiona Child, et al.
British Journal of Dermatology (2018) Vol. 180, Iss. 3, pp. 496-526
Closed Access | Times Cited: 131
Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox
American Journal of Hematology (2019) Vol. 94, Iss. 9, pp. 1027-1041
Open Access | Times Cited: 118
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox
American Journal of Hematology (2022) Vol. 98, Iss. 1, pp. 193-209
Open Access | Times Cited: 51
U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma
Julia Scarisbrick, Stephen Morris, Richard Azurdia, et al.
British Journal of Dermatology (2012) Vol. 168, Iss. 1, pp. 192-200
Closed Access | Times Cited: 97
Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
Christina E. Wells, Srividya Bhaskara, Kristy R. Stengel, et al.
PLoS ONE (2013) Vol. 8, Iss. 7, pp. e68915-e68915
Open Access | Times Cited: 96
The Results of Low-Dose Total Skin Electron Beam Radiation Therapy (TSEB) in Patients With Mycosis Fungoides From the UK Cutaneous Lymphoma Group
Stephen Morris, Julia Scarisbrick, J. Frew, et al.
International Journal of Radiation Oncology*Biology*Physics (2017) Vol. 99, Iss. 3, pp. 627-633
Closed Access | Times Cited: 75
Cutaneous T‐cell lymphoma: 2014 Update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2014) Vol. 89, Iss. 8, pp. 837-851
Open Access | Times Cited: 67
Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy
Hiroaki Kamijo, Tomomitsu Miyagaki
Current Treatment Options in Oncology (2021) Vol. 22, Iss. 2
Closed Access | Times Cited: 51
Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations
Neha Mehta, Alan S. Wayne, Youn H. Kim, et al.
Clinical Lymphoma Myeloma & Leukemia (2011) Vol. 12, Iss. 1, pp. 20-25
Open Access | Times Cited: 73
Bexarotene: a promising anticancer agent
Liyan Qu, Xiuwen Tang
Cancer Chemotherapy and Pharmacology (2009) Vol. 65, Iss. 2, pp. 201-205
Closed Access | Times Cited: 71
Cutaneous T‐cell lymphoma: 2011 update on diagnosis, risk‐stratification, and management
Ryan A. Wilcox
American Journal of Hematology (2011) Vol. 86, Iss. 11, pp. 928-948
Open Access | Times Cited: 71
Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas
Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, et al.
Critical Reviews in Oncology/Hematology (2016) Vol. 99, pp. 214-227
Open Access | Times Cited: 47
Anticancer Drug-induced Thyroid Dysfunction
Saptarshi Bhattacharya, Alpesh Goyal, Parjeet Kaur, et al.
touchREVIEWS in Endocrinology (2020) Vol. 16, Iss. 1, pp. 32-32
Open Access | Times Cited: 43
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches
David M. Weiner, Joseph S. Durgin, Maria Wysocka, et al.
Journal of the American Academy of Dermatology (2020) Vol. 84, Iss. 3, pp. 597-604
Open Access | Times Cited: 42
Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox
American Journal of Hematology (2020) Vol. 95, Iss. 10, pp. 1209-1213
Open Access | Times Cited: 39
Page 1 - Next Page

Scroll to top